Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
93.7 USD | +0.75% | +3.86% | +2.03% |
Apr. 25 | Transcript : Blueprint Medicines Corporation - Special Call | |
Mar. 22 | Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- The company is not the most generous with respect to shareholders' compensation.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.03% | 5.84B | B- | ||
+2.11% | 42.75B | B | ||
+47.58% | 41.61B | A | ||
+12.26% | 41.34B | B- | ||
-12.36% | 26.59B | C | ||
+8.65% | 25.49B | B- | ||
-23.10% | 18.12B | B | ||
+30.90% | 12.24B | C+ | ||
-1.56% | 11.76B | C+ | ||
+8.93% | 11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BPMC Stock
- Ratings Blueprint Medicines Corporation